耐药性黑色素瘤可能易受丝氨酸合成抑制剂的影响。
Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis.
机构信息
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
J Invest Dermatol. 2020 Nov;140(11):2114-2116. doi: 10.1016/j.jid.2020.05.103.
NRAS-driven melanomas frequently develop resistance to MAPK/extracellular signal-regulated kinase kinase inhibitors (MEKis), which limits their therapeutic utility. Nguyen et al. (2020) show that MEKi-resistant cells upregulate phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine synthesis. Suppression of PHGDH rendered cells sensitive to MEKis, suggesting that PHGDH may be a therapeutic target for melanoma.
NRAS 驱动的黑色素瘤常对丝裂原活化蛋白激酶/细胞外信号调节激酶激酶抑制剂（MEKi）产生耐药性，限制了其治疗用途。Nguyen 等人（2020 年）表明，MEKi 耐药细胞上调磷酸甘油酸脱氢酶（PHGDH），这是丝氨酸合成中的限速酶。抑制 PHGDH 使细胞对 MEKi 敏感，表明 PHGDH 可能是黑色素瘤的治疗靶点。
Zotero 插件